The study of biomarkers for intractable vascular anomalies and associated with pharmacological action of sirolimus
Not Applicable
Recruiting
- Conditions
- Vascular anomalies
- Registration Number
- JPRN-UMIN000029173
- Lead Sponsor
- Gifu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with a history of hypersensitivity to ingredients of this drug 2. Patients with serious liver and renal disorders 3. Patients with symptoms that affect cytokine value of such obvious infection at the time of specimen collection 4. Patients must also avoid strong inducers of CYP3A4 5. Past usage of mTOR inhibitors or other molecular target drugs relating mTOR pathway 6. Patient who is judged inappropriate to participate in this study by the investigators
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The relativity between the efficacy and safety of the sirolimus treatment and cytokine
- Secondary Outcome Measures
Name Time Method The difference of disease-specific biomarkers for vascular anomalies. The change of cytokine after sirolimus treatment.